Assertio Holdings, Inc. · NASDAQ (us_market)
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-11-11$13.80 RISE2026-03-11$11.50 PEAK2026-05-26$23.46 196d | -16.7% 120d | Missed | Missed | — | — | +104.0% 76d | Missed |
DROP2025-09-18$14.55 RISE2025-12-31$9.07 PEAK2026-03-26$19.53 189d | -37.7% 104d | Missed | Missed | — | — | +115.3% 85d | Missed |
DROP2024-12-02$15.30 RISE2025-04-08$7.95 PEAK2025-05-19$10.65 168d | -48.0% 127d | Missed | Missed | — | — | +34.0% 41d | Missed |
DROP2024-07-16$26.25 RISE2024-11-15$12.15 PEAK2024-12-02$15.30 139d | -53.7% 122d | Missed | Missed | — | — | +25.9% 17d | Missed |
DROP2024-07-16$26.25 RISE2024-08-14$16.05 PEAK2024-09-19$20.25 65d | -38.9% 29d | Missed | Missed | — | — | +26.2% 36d | Missed |
DROP2024-07-16$26.25 RISE2024-08-12$16.05 PEAK2024-09-19$20.25 65d | -38.9% 27d | Missed | Missed | — | — | +26.2% 38d | Missed |
DROP2023-12-26$17.25 RISE2024-04-18$11.25 PEAK2024-07-16$26.25 203d | -34.8% 114d | Missed | Missed | — | — | +133.3% 89d | Missed |
DROP2023-10-17$37.50 RISE2024-02-21$11.85 PEAK2024-05-06$18.30 202d | -68.4% 127d | Missed | Missed | — | — | +54.4% 75d | Missed |
DROP2023-10-06$38.55 RISE2024-02-08$11.85 PEAK2024-05-06$18.30 213d | -69.3% 125d | Missed | Missed | — | — | +54.4% 88d | Missed |
DROP2023-09-28$39.60 RISE2024-02-07$11.85 PEAK2024-03-13$17.10 167d | -70.1% 132d | Missed | Missed | — | — | +44.3% 35d | Missed |
DROP2023-09-28$39.60 RISE2024-02-05$11.85 PEAK2024-03-13$17.10 167d | -70.1% 130d | Missed | Missed | — | — | +44.3% 37d | Missed |
DROP2023-09-28$39.60 RISE2024-02-02$11.85 PEAK2024-03-13$17.10 167d | -70.1% 127d | Missed | Missed | — | — | +44.3% 40d | Missed |
DROP2023-07-31$85.35 RISE2023-11-30$15.30 PEAK2023-12-04$17.70 126d | -82.1% 122d | Missed | Missed | — | — | +15.7% 4d | Missed |
DROP2023-05-11$114.90 RISE2023-08-04$43.65 PEAK2023-08-21$51.75 102d | -62.0% 85d | Missed | Missed | — | — | +18.6% 17d | Missed |
DROP2023-03-09$99.90 RISE2023-04-26$75.00 PEAK2023-05-11$114.90 63d | -24.9% 48d | Missed | Missed | — | — | +53.2% 15d | Missed |
1–15 / 31 1 / 3 | |||||||
No scored news yet for a sentiment trend.
Lake Street analyst Thomas Flaten maintains Assertio Hldgs (NASDAQ:ASRT) with a Hold and raises the price target from $21.8 to $23.5.
Garda Therapeutics, Inc. entered into a definitive agreement to acquire Assertio Holdings, Inc. for approximately $120 million on April 8, 2026. Under the terms of the agreement, Garda will promptly...
Zydus Worldwide DMCC agreed to acquire Assertio Holdings, Inc. for approximately $170 million on May 13, 2026. A cash consideration valued at $23.5 per share and will be paid by Zydus Worldwide DMCC....
Assertio’s latest offer represents a roughly 31% premium over an initial acquisition proposal. Elsewhere, Kyverna is readying a first-of-its-kind approval application and AC Immune is swapping CEOs.
Assertio Holdings Inc: Assertio to be acquired by Zydus Worldwide DMCC for $23.50 per share in cash Assertio Holdings Inc - all-cash tender offer valued at $166.4 million Assertio Holdings Inc...
By Nicholas G. Miller A subsidiary of Zydus Lifesciences agreed to acquire pharmaceutical company Assertio Holdings for $166.4 million, topping Assertio's previous sale agreement with Garda...
Assertio Holdings, Inc. (NASDAQ:ASRT) ("Assertio" or the "Company") today announced that, following an engagement process outlined under the revised merger agreement (the "Garda Merger Agreement") with Garda
Assertio Holdings Inc: Assertio and Garda mutually agree to delay launch of tender offer Assertio Holdings Inc - Co and Garda delay tender offer launch to May 14, 2026 Assertio Holdings Inc -...
Assertio (ASRT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Assertio Holdings Inc: Assertio and Garda mutually agree to postpone commencement of tender offer Assertio Holdings Inc - co and Garda postpone tender offer commencement to May 8, 2026...
The modelled fair value for Assertio Holdings sits at US$21.33 per share, with no adjustment to the central price target in the latest update. This stable target reflects how recent analyst commentary has shifted toward weighing risk and upside around the takeover agreement, rather than chasing higher headline numbers. As you read on, you will see how this steady US$21.33 anchor fits into the evolving story and what to watch if you are tracking Assertio’s next moves. Analyst Price Targets...
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Assertio Hldgs (NASDAQ:ASRT) with a Neutral and raises the price target from $18 to $21.8.
The session on Monday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Assertio Holdings Inc: Assertio announces amended and restated merger agreement with Garda Therapeutics ASSERTIO HOLDINGS INC: increased all-cash tender offer price of $21.80 per share - or...
Increased All-Cash Tender Offer Price of $21.80 per share – or $153.2 MillionNew Tender Offer Price Represents 21.1% Premium to Prior OfferAssertio Holdings, Inc. (NASDAQ:ASRT) ("Assertio" or the "Company") today
Here is how Assertio (ASRT) and BrightSpring Health Services, Inc. (BTSG) have performed compared to their sector so far this year.
Assertio Holdings, Inc. , today announced that it has reached a mutual agreement with Garda Therapeutics, Inc. to extend the deadline to commence the previously announced tender offer to acquire all...
Assertio Holdings Inc:Assertio provides update on Garda Therapeutics tender process Assertio Holdings Inc - Garda to commence tender offer for Assertio shares on April 29, 2026 Assertio...
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ASRT | +26.91% | +99.15% | +158.43% | +136.77% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +23.94% | +104.87% | +161.88% | +124.08% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| RenTech | quant | 228.6K | $4.36M | 0.01% | Added+19.9% | 2026-03-31 |
| TwoSigma | quant | 33.6K | $639.98K | 0.00% | Added+79.8% | 2026-03-31 |
| StateStreet | passive | 27.8K | $529.33K | 0.00% | Added+8.2% | 2026-03-31 |
| FidelityFMR | fundamental | 23 | $438 | 0.00% | Trimmed-72.6% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-10upcoming | -1.10 | — | — |
| 2026-05-08 | -2.10 | -2.93 | -39.36% |
| 2026-03-16 | -1.80 | -1.06 | +41.11% |
| 2025-11-10 | — | 2.70 | — |
| 2025-08-11 | -0.07 | 0.30 | +500.00% |
| 2025-05-12 | -0.15 | -0.60 | -300.00% |
| 2025-03-12 | 0.20 | -0.45 | -325.00% |
| 2024-11-11 | — | 0.45 | — |
| 2024-08-07 | 0.25 | 0.30 | +20.00% |
| 2024-05-06 | -0.15 | 0.60 | +500.00% |
| 2024-03-11 | 0.30 | 1.65 | +450.00% |
| 2023-11-08 | 1.43 | 0.15 | -89.47% |
| 2023-08-03 | 3.30 | 2.85 | -13.64% |
| 2023-05-09 | 3.30 | 4.35 | +31.82% |
| 2023-03-08 | 3.00 | 4.80 | +60.00% |
| 2022-11-08 | 1.65 | 3.30 | +100.00% |